Finance and funding: latest news

Finance and funding features

Finance and funding news from aidsmap

More news

Finance and funding news selected from other sources

  • NHS asks Nice to delay ground-breaking hepatitis C drug

    Nice is due to finish its final assessment of sofosbuvir in January. It is usual for them to give the NHS three months to find the money or put staff – if needed – in place. NHS England is thought to have asked them to delay this by six months.

    19 November 2014 | Channel 4 News (blog)
  • South Africa to spend $2.2 billion on HIV drugs in next two years

    South Africa plans to spend $2.2 billion over two years to buy HIV/AIDS drugs for public hospitals, a government minister said on Monday, as a study shows the prevalence of the virus is rising.

    18 November 2014 | Reuters
  • UK has 'signed a death warrant' for South Africans with HIV-Aids

    One of the world’s leading Aids activists has accused Britain of “signing a death warrant” for South Africans in need of treatment after withdrawing aid from the Treatment Action Campaign, which now faces ruin.

    05 November 2014 | The Guardian
  • TB activists call for a bigger piece of the pie from the Global Fund

    Today (October 31) TB activists interrupted the plenary session at the 45th Conference on Lung Health, calling on the Global Fund and partners to increase the amount of funds allocated to TB without jeopardizing funding to HIV and malaria and other diseases.

    04 November 2014 | TB Online
  • How Will Generic Drugs Affect HIV Treatment in the U.S.?

    In the U.S., in that many of the antiretroviral drugs that are commonly used today are approaching their patent expirations. So we can begin to conceptualize the use of generics in the U.S. and the potential cost savings. An Interview With Treatment Action Group's Tim Horn.

    31 October 2014 | The Body
  • Elton John AIDS Foundation Invests in MSM, LGBT Programs

    The Elton John AIDS Foundation is joining PEPFAR and HRC to fund HIV programs focused on the U.S. LGBT population and South African men who have sex with men.

    31 October 2014 | Poz magazine news
  • GSK eyes prime FTSE 100 slot for standalone HIV drugs business

    GlaxoSmithKline, battered by weak U.S. drug sales and a bribery scandal in China, is looking to float ViiV, its fast-growing HIV drugs business as part of a recovery plan that includes a fresh round of cost cutting.

    26 October 2014 | Reuters
  • 2014 Report on Tuberculosis Research Funding Trends, 2005–2013

    Worldwide, governments, foundations, and companies invested US$676.7 million in research to develop new drugs, vaccines, and diagnostics against tuberculosis (TB) in 2013—barely one-third of the US$2 billion that experts estimate the world must spend each year to end the global TB epidemic—according to an analysis released today by Treatment Action Group (TAG).

    22 October 2014 | TAG
  • IDWeek 2014: Behavioral and Financial Incentives May Improve HIV Treatment Outcomes

    While making medications free can remove barriers to access for individuals who cannot pay for treatment, data suggest that for most people accessing care in industrialized countries, "making medications available for free or low cost will not solve problems with medication non-adherence," according to a presentation by Kevin Volpp from the University of Pennsylvania last week at IDWeek 2014 in Philadelphia.

    16 October 2014 | HIVandHepatitis.com
  • Unique 'pay if you clear' proposal for new hepatitis drug

    The NHS in Scotland could be reimbursed for the cost of a new hepatitis drug if sufferers fail to clear the virus. The novel proposal was revealed after the drug Olysio was cleared for use by the Scottish Medicines Consortium (SMC).

    15 October 2014 | BBC
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.